Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.11 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative front-line health care workers and hospital patients.
Description: Percent of healthcare workers that become positive for COVID-19 during the study.
Measure: Percent of healthcare workers testing positive for COVID-19. Time: 3 weeksDescription: Percent of patients that become positive for COVID-19 during the study.
Measure: Percent of patients testing positive for COVID-9. Time: 2 weeksDescription: Patients will rate the ease of use for PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased ease of use (1="easy") while higher scores indicate increased difficulty (5="impossible").
Measure: PVP-I Ease of Use Time: 3 weeksDescription: Patients will rate the comfort of PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased comfort (1="not so bad") while higher scores indicate discomfort (5="worst pain of my life").
Measure: PVP-I Comfort Time: 3 weeksDescription: Participants will fill out a daily questionaire assessing treatment frequency. Adherence will be calculated as the percent of correct dosing.
Measure: Adherence to treatment protocol Time: 3 weeksPovidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative front-line health care workers and hospital patients.
Description: Percent of healthcare workers that become positive for COVID-19 during the study.
Measure: Percent of healthcare workers testing positive for COVID-19. Time: 3 weeksDescription: Percent of patients that become positive for COVID-19 during the study.
Measure: Percent of patients testing positive for COVID-9. Time: 2 weeksDescription: Patients will rate the ease of use for PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased ease of use (1="easy") while higher scores indicate increased difficulty (5="impossible").
Measure: PVP-I Ease of Use Time: 3 weeksDescription: Patients will rate the comfort of PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased comfort (1="not so bad") while higher scores indicate discomfort (5="worst pain of my life").
Measure: PVP-I Comfort Time: 3 weeksDescription: Participants will fill out a daily questionaire assessing treatment frequency. Adherence will be calculated as the percent of correct dosing.
Measure: Adherence to treatment protocol Time: 3 weeks